APEIRON was founded in 2003 by Josef Penninger to translate academic basic research into therapeutic products in diseases with high unmet need, namely cancer. The operations of the Company started in 2005, initially focusing on discovery projects. Since its inception, APEIRON has substantially devoted its resources to raising capital and developing innovative projects. The Company has since inception identified and developed potential product candidates and conducts pre-clinical and clinical trials in different tumor indications.
On 1 January 2022 the operational R&D activities of APEIRON were spun off into invIOs GmbH, including all staff and related assets.